
Otsuka to take over Astellas’ Cefixime business
pharmafile | June 7, 2019 | News story | Medical Communications | APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma
Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.
The agreement gives Otsuka the right to sell Cefixime and supply the active pharmaceutical ingredient (API) to overseas licensees.
The move comes as part of an effort from Otsuka to strengthen their grounding in the API business.
Astellas’ Cefixime is a third generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria. The antibiotic is prescribed around the world.
Otsuka said they intend to further strengthen their business through new technologies as they take advantage of key technologies.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






